穴位埋线治疗对多囊卵巢综合征患者代谢和激素水平的影响

徐颖; 米海霞; 杨洋

doi:10.16766/j.cnki.issn.1674-4152.003475

穴位埋线治疗对多囊卵巢综合征患者代谢和激素水平的影响

doi: 10.16766/j.cnki.issn.1674-4152.003475

徐颖¹,
米海霞^2, ,,
杨洋¹

1.
温州市人民医院针灸推拿科，浙江温州 325000
2.
温州市人民医院中医妇科

基金项目:

浙江省中医药科技计划项目 2023ZF046

详细信息

通讯作者:
米海霞，E-mail：575924022@qq.com

中图分类号: R245.91 R711.75
计量
- 文章访问数: 277
- HTML全文浏览量: 100
- PDF下载量: 12
- 被引次数: 0
出版历程
- 收稿日期: 2023-10-11
- 网络出版日期: 2024-05-29

Effect of acupoint catgut embedding therapy on metabolism and hormone levels in patients with polycystic ovary syndrome

XU Ying¹,
MI Haixia^{2
, ,},
YANG Yang¹

1.
Department of Acupuncture and Massage, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, China

摘要

摘要: 目的多囊卵巢综合征(PCOS)的发病率呈持续上升的趋势，严重困扰广大女性患者，穴位埋线治疗是一种改良式针刺疗法，本研究将探讨穴位埋线治疗对PCOS患者代谢和激素水平的影响。方法选取温州市人民医院2021年3月—2023年1月收治的PCOS患者156例纳入研究，根据随机数字表法分为2组，对照组和观察组，观察过程因患者依从性差等原因脱落8例，故总入组例数为148例，2组各74例。对照组参照《中国PCOS诊断和治疗指南》予以常规治疗，观察组在对照组基础上予以穴位埋线治疗，观察2组治疗后临床疗效、糖脂代谢[甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、稳态模型胰岛素抵抗指数(HOMA-IR)]、激素[睾酮素(T)、黄体生成激素(LH)、卵泡生成激素(FSH)]及卵巢储备功能[抗缪勒管激素(AMH)、抑制素B(INHB)、窦卵泡计数]。结果观察组总有效61例，总有效率为82.43%(61/74)，较对照组的总有效率67.57%(50/74)高(χ²=4.360，P=0.037)；观察组治疗后TG、TC、LDL-C、FINS、HbA1c、HOMA-IR低于对照组，HDL-C高于对照组(均P < 0.05)；观察组FSH、AMH、INHB高于对照组，T、LH、窦卵泡计数低于对照组(均P < 0.05)。结论穴位埋线治疗可调节PCOS患者代谢和激素水平，改善卵巢储备功能，疗效显著。
- 穴位埋线 /
- 多囊卵巢综合征 /
- 糖脂代谢 /
- 激素 /
- 卵巢储备
Abstract: Objective The incidence of polycystic ovary syndrome (PCOS) is on the rise, which seriously puzzles the majority of female patients. Acupoint catgut embedding therapy is an improved acupuncture therapy. This study will explore the influence of acupoint catgut embedding therapy on the metabolism and hormone levels of PCOS patients. Methods A total of 156 PCOS patients admitted to Wenzhou People ' s Hospital from March 2021 to January 2023 were selected as the study objects and were divided into a control group and an observation group according to the random number table method. During the observation process, 8 cases fell out due to poor patient compliance and other reasons, so the total number of enrolled cases was 148, with 74 cases in each group. The control group was given routine treatment according to "Chinese Guidelines for the Diagnosis and Treatment of PCOS". The observation group received acupoint catgut embedding therapy based on the control group. Clinical efficacy, glucose and lipid metabolism [triglyceride (TG), total cholesterol (TC), high-density liptein cholesterol (HDL-C) and low-density lipoprotein (LDL-C), fasting insulin (FINS), glycated hemoglobin (HbA1c), homeostasis model insulin resistance index (HOMA-IR)], hormone [testosterone (T), luteinogen hormone (LH), follicle-forming hormone (FSH)] and ovarian reserve function [anti-Mullerian hormone (AMH), statin B (INHB), sinus follicle count] in the two groups after treatment were observed. Results There were 61 effective cases in the observation group, and the total effective rate was 82.43% (61/74), which was higher than that of the control group [67.57% (50/74), χ²=4.360, P=0.037]. After treatment, TG, TC, LDL-C, FINS, HbA1c, and HOMA-IR in the observation group were lower than the control group, and HDL-C was higher than the control group (P < 0.05). FSH, AMH, and INHB in the observation group were higher than those in the control group, and T, LH, and sinus follicle count were lower than those in the control group (P < 0.05). Conclusion Acupoint catgut embedding therapy can regulate the metabolism and hormone levels of PCOS patients, improve ovarian reserve function, and have a significant effect.
- Acupoint embedding /
- Polycystic ovary syndrome /
- Glycolipid metabolism /
- Hormone /
- Ovarian reserve

HTML全文

表 1 2组PCOS患者基线资料比较

Table 1. Comparison of baseline data of PCOS patients between the two groups

组别	例数	年龄(x±s，岁)	病程(x±s, 年)	BMI(x±s)	家族史[例(%)]	腰臀比(x±s)
观察组	74	35.62±4.68	4.23±1.32	25.23±2.34	12(16.22)	0.84±0.05
对照组	74	34.98±5.01	4.19±1.42	25.67±2.18	14(18.92)	0.83±0.06
统计量		0.803^a	0.177^a	1.184^a	0.187^b	1.101^a
P值		0.423	0.859	0.239	0.666	0.273
注: ^a为t值，^b为χ²值。

下载: 导出CSV

表 2 2组PCOS患者临床疗效比较[例(%)]

Table 2. Comparison of clinical efficacy of PCOS patients between the two groups[cases(%)]

组别	例数	痊愈	显效	有效	无效	总有效
观察组	74	25(33.78)	24(32.43)	12(16.22)	13(17.57)	61(82.43)
对照组	74	19(25.68)	14(18.92)	17(22.97)	24(32.43)	50(67.57)
统计量	2.095^a					4.360^b
P值	0.036					0.037
注: ^a为Z值，^b为χ²值。

下载: 导出CSV

表 3 2组PCOS患者代谢水平比较(x±s)

Table 3. Comparison of metabolic levels of PCOS patients between the two groups(x±s)

组别	例数	TG(mmol/L)		TC(mmol/L)			HDL-C(mmol/L)			LDL-C(mmol/L)
组别	例数	治疗前	治疗后	治疗前	治疗后		治疗前	治疗后		治疗前	治疗后
观察组	74	3.55±0.32	2.36±0.41^b	5.19±0.44	4.11±0.32^b		1.05±0.22	1.75±0.35^b		4.26±1.03	1.98±0.61^b
对照组	74	3.57±0.34	2.55±0.38^b	5.21±0.46	4.34±0.37^b		1.07±0.24	1.62±0.27^b		4.28±1.07	2.23±0.57^b
统计量		0.368^a	9.123^c	0.270^a	17.118^c		0.528^a	4.253^c		0.116^a	4.087^c
P值		0.713	0.003	0.787	＜0.001		0.598	0.042		0.908	0.045

组别	例数	FINS(mmol/L)			HbA1c(%)				HOMA-IR
组别	例数	治疗前	治疗后		治疗前	治疗后			治疗前	治疗后
观察组	74	24.26±2.35	10.65±3.21^b		5.96±1.05	5.01±0.76^b			5.44±1.21	2.98±0.74^b
对照组	74	23.98±2.43	13.65±2.97^b		5.91±1.07	5.31±0.81^b			5.37±1.27	3.54±0.85^b
统计量		0.713^a	37.583^c		0.287^a	5.200^c			0.343^a	24.327^c
P值		0.477	＜0.001		0.775	0.024			0.732	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 4 2组PCOS患者激素水平比较(x±s)

Table 4. Comparison of hormone levels between the two groups of PCOS patients(x±s)

组别	例数	FSH(IU/L)		LH(IU/L)		T(nmol/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	74	5.68±1.21	7.64±2.01^b	17.26±3.56	10.02±2.37^b	1.32±0.31	0.78±0.15^b
对照组	74	5.77±1.19	6.18±1.89^b	16.79±4.02	12.67±2.98^b	1.34±0.29	0.92±0.21^b
统计量		0.456^a	13.274^c	0.753^a	32.317^c	0.405^a	22.718^c
P值		0.649	＜0.001	0.453	＜0.001	0.686	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 5 2组PCOS患者卵巢储备功能比较(x±s)

Table 5. Comparison of ovarian reserve function between the two groups of PCOS patients(x±s)

组别	例数	AMH(ng/dL)		INHB(ng/L)		窦卵泡计数(个)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	74	5.46±0.69	8.16±1.32^b	112.02±10.34	142.69±12.64^b	25.26±4.25	10.35±2.67^b
对照组	74	5.51±0.74	7.44±1.21^b	113.45±11.02	131.57±13.57^b	24.98±3.97	12.05±2.98^b
统计量		0.425^a	27.730^c	0.814^a	11.788^c	0.414^a	22.883^c
P值		0.671	0.001	0.417	＜0.001	0.679	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

参考文献(21)

[1]	SADEGHI H M, ADELI I, CALINA D, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing[J]. Int J Mol Sci, 2022, 23(2): 583. doi: 10.3390/ijms23020583
[2]	STENER-VICTORIN E, PADMANABHAN V, WALTERS K A, et al. Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome[J]. Endocr Rev, 2020, 41(4): 10.
[3]	严欣, 王连红, 郭云梅, 等. 中国多囊卵巢综合征患者焦虑抑郁患病率的meta分析[J]. 中国医药导报, 2022, 19(27): 92-96. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202227020.htm YAN X, WANG L H, GUO Y M, et al. Meta analysis on prevalence of anxiety and depression of patients with polycystic ovary syndromen in China[J]. China Medical Herald, 2022, 19(27): 92-96. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202227020.htm
[4]	张曙光, 周航, 杨翼, 等. 多囊卵巢综合征中医药治疗机制的研究热点趋势可视化图谱研究[J]. 成都中医药大学学报, 2022, 45(3): 92-97. https://www.cnki.com.cn/Article/CJFDTOTAL-CDZY202203019.htm ZHANG S G, ZHOU H, YANG Y, et al. Progress on Hot Spot Analysis and Development Trend of Traditional Chinese Medicine Treatment Mechanism of Polycystic Ovary Syndrome Research on Visual Spectrogram[J]. Journal of Chengdu University of Traditional Chinese Medicine, 2022, 45(3): 92-97. https://www.cnki.com.cn/Article/CJFDTOTAL-CDZY202203019.htm
[5]	陈飞. 针刺结合芎归二陈汤加减治疗多囊卵巢综合征临床观察[J]. 实用中医药杂志, 2023, 39(2): 225-227. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYAO202302005.htm CHEN F. Clinical observation of acupuncture combined with Xionggui Erchen Decoction in the treatment of polycystic ovary syndrome[J]. Journal of Practical Traditional Chinese Medicine, 2023, 39(2): 225-227. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYAO202302005.htm
[6]	李敏, 张新普, 陈浩雄, 等. 穴位埋线法发展概述[J]. 河南中医, 2023, 43(5): 800-803. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY202305031.htm LI M, ZHANG X F, CHEN H X, et al. Overview of the Development of Acupoint Catgut Embedding Therapy[J]. Henan Traditional Chinese Medicine, 2023, 43(5): 800-803. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY202305031.htm
[7]	中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ201810010.htm
[8]	刘敏如, 欧阳惠卿. 实用中医妇科学[M]. 上海: 上海科学技术出版社, 2010: 68-77. LIU M R, OUYANG H Q. Practical TCM gynecology[M]. Shanghai: Shanghai Science and Technology Press, 2010: 68-77.
[9]	中华医学会心血管病学分会, 中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志, 2018, 34(5): 421-434. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB201805001.htm
[10]	郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 239-242. ZHENG X Y. Guiding Principles of Clinical research on New Chinese Medicine (Trial)[M]. Beijing: Academy of Chinese Medical Science and Technology Press, 2002: 239-242.
[11]	王景潇, 李嘉, 沈卫东. 多囊卵巢综合征的中医分型及针灸治疗[J]. 上海医药, 2021, 42(13): 32-34, 62. https://www.cnki.com.cn/Article/CJFDTOTAL-SYIY202113010.htm WANG J X, LI J, SHEN W D. TCM classification and acupuncture treatment of polycystic ovary syndrome[J]. Shanghai Medical & Pharmaceutical Journal, 2021, 42(13): 32-34, 62. https://www.cnki.com.cn/Article/CJFDTOTAL-SYIY202113010.htm
[12]	姚鑫, 刘振国, 黄作阵. 《灵枢·终始》针刺补泻取穴考[J]. 北京中医药大学学报, 2019, 42(9): 730-733. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYB201909005.htm YAO X, LIU Z G, HUANG Z Z. A study on acupoint selection for supplementation/drainage needling in the chapter "Zhongshi" in Lingshu[J]. Journal of Beijing University of Traditional Chinese Medicine, 2019, 42(9): 730-733. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYB201909005.htm
[13]	王少军, 朱兵. 卵巢-体表的相关性与经穴关系的研究[J]. 中国针灸, 2007, 27(10): 761-765. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZE200710019.htm WANG S J, ZHU B. Study on relation of ovary-body surface correlativity with acupoints[J]. Chinese Acupuncture & Moxibustion, 2007, 27(10): 761-765. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZE200710019.htm
[14]	MUHARAM R, PH D, SRILESTARI A, et al. Combination of electroacupuncture and pharmacological treatment improves insulin resistance in women with polycystic ovary syndrome: double-blind randomized clinical trial[J]. Int J Reprod Biomed, 2022, 20(4): 289-298.
[15]	YANG H, XIAO Z Y, YIN Z H, et al. Efficacy and safety of acupuncture for polycystic ovary syndrome: an overview of systematic reviews[J]. J Integr Med, 2023, 21(2): 136-148.
[16]	赵晓君, 范郁山, 冯卓, 等. 基于数据挖掘探讨针灸治疗多囊卵巢综合征伴胰岛素抵抗的选穴规律[J]. 广西医学, 2023, 45(1): 45-50. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYX202301010.htm ZHAO X J, FAN Y S, FENG Z, et al. Acupoint-selected rules of acupuncture and moxibustion for the treatment of polycystic ovarian syndrome with concomitant insulin resistance: an exploration based on data mining[J]. Guangxi Medical Journal, 2023, 45(1): 45-50. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYX202301010.htm
[17]	DE OLIVEIRA N M, MACHADO J, HUANG Z, et al. Acupuncture in women with human polycystic ovary/ovarian syndrome: protocol for a randomized controlled trial[J]. Healthcare (Basel), 2022, 10(10): 1999. DOI: 10.3390/healthcare10101999.
[18]	WU J M, NING Y, YE Y Y, et al. Effects of acupuncture on endometrium and pregnancy outcomes in patients with polycystic ovarian syndrome undergoing in vitro fertilization-embryo transfer: a randomized clinical trial[J]. Chin J Integr Med, 2022, 28(8): 736-742.
[19]	RUDNICKA E, KUNICKI M, CALIK-KSEPKA A, et al. Anti-Müllerian hormone in pathogenesis, diagnostic and treatment of PCOS[J]. Int J Mol Sci, 2021, 22(22): 12507. DOI: 10.3390/ijms222212507.
[20]	秦薇, 黄筱竑, 黄慧莲. HIF-1α、VEGF及AMH在多囊卵巢综合征中的表达及其临床意义[J]. 中华全科医学, 2021, 19(10): 1693-1696. doi: 10.16766/j.cnki.issn.1674-4152.002144?viewType=HTML QIN W, HUANG X H, HUANG H L. Expression and clinical significance of HIF-1α, VEGF and AMH in patients with polycystic ovary syndrome[J]. Chinese Journal of General Practice, 2021, 19(10): 1693-1696. doi: 10.16766/j.cnki.issn.1674-4152.002144?viewType=HTML
[21]	周雨雨, 杨硕, 熊琳琳, 等. 穴位埋线辅助治疗对超重或肥胖伴2型糖尿病患者FBG、PBG、HbA1c的影响[J]. 云南中医药大学学报, 2023, 46(4): 11-15, 24. https://www.cnki.com.cn/Article/CJFDTOTAL-YNZY202304003.htm ZHOU Y Y, YANG S, XIONG L L, et al. Effects of Acupoint Catgut Embedding on FBG, PBG and HbAlc in Overweight or Obese Patients with Type 2 Diabetes Mellitus[J]. Journal of Yunnan University of Chinese Medicine, 2023, 46(4): 11-15, 24. https://www.cnki.com.cn/Article/CJFDTOTAL-YNZY202304003.htm